clinical trial · NCT07556822
Phase I Study of HRS-3005 in B-cell Malignancies
Jiangsu HengRui Medicine Co., Ltd.·phase1·recruiting·n = 190
B-cell MalignancyHRS-3005
brief summary
The study is being conducted to evaluate the safety and tolerability of HRS-3005. To explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-3005 in patients with B-cell malignancy.
started
Jun 3, 2026
primary completion
Oct 1, 2028
completion
Dec 1, 2028
last updated
Jun 10, 2026
official title
An Open-Label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-3005 in Patients With B-cell Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol